Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Nurix Therapeutics (NRIX – Research Report) on April 2. The company’s ...

In a report released on April 2, Michael Cherny from Leerink Partners maintained a Buy rating on McKesson (MCK – Research Report), with a price ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. Analyst Price Forecast Suggests 419.11% Upside ...

As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and mass layoffs throughout the FDA raise concerns about the agency’s ability to ...

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares. Q4 results featured a continuation of challenges around ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of AxoGen in a research note issued to investors ...

Investment analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Turnstone Biologics in a report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

As of March 4, 2025, the average one-year price target for CorMedix is $16.52/share. The forecasts range from a low of $12.12 to a high of $19.95. The average price target represents an increase ...

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink Partners analysts said that the risks from Trump’s tariffs on the biopharma ...